Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE  >  Green Cross Corp    006280   KR7006280002

GREEN CROSS CORP

(006280)
My previous session
Most popular
  Report  
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Green Cross : GC Pharma Reports Full Year 2018 Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 09:02am EST

Delivers Continued Momentum in 2018 Through Broadly-based Sales Growth

YONGIN, South Korea, Feb. 12, 2019 /CNW/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended 31 December 2018.

Key Figures(K-IFRS)

Full Year 2018(KRW billion)

Growth(1)

Total revenues

1334.9

+3.6%

Operating income

50.2

(44.4)%

EBITDA

90.4

(28.8) %

(1) Results and percentages to the full financial year 2017

Q4 2018

  • Total revenues of KRW 346.7B and +6.3% YoY growth
  • Meaningful Q4 local sales of KRW 230.8B and +8.5% YoY growth and international sales reaching KRW 66.6B
  • Diversified business model moderates negative effects from anticipated decline in in-licensed vaccines sales
  • Anticipated decline in operating profit amplified by year-round high cost of sales

FY 2018

  • Total revenues of KRW 1,334.9B and +3.6% YoY growth
  • International businesses(+10.1% YoY growth) deliver another year of solid growth while local sales up slightly
  • EBITDA margin impacted by cost of sales to revenue ratio up +2.6pps to 74.1% due to ahead investments in global expansion plus upping R&D +12.3%

EC Huh, Ph.D., GC Pharma President, commented:

"Our business focus remains on creating significant value for shareholders and other stakeholders. We further strengthened our future opportunities in 2019 and expect to generate solid growth."

About GC Pharma

GC Pharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name.

This release includes forward-looking statements, which express the current beliefs and expectations of GC Pharma's management. Such statements speak only as of the date on which they are made and the company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Cision
View original content:http://www.prnewswire.com/news-releases/gc-pharma-reports-full-year-2018-results-300793841.html

SOURCE GC Pharma

© Canada Newswire, source Canada Newswire English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GREEN CROSS CORP
02/12GREEN CROSS : GC Pharma Reports Full Year 2018 Results
AQ
2018GREEN CROSS CORP : Ex-dividend day for final dividend
FA
2018GREEN CROSS : GC Pharma Reports Q3 2018 Results
AQ
2018GREEN CROSS : GC Pharma Reports Q2 2018 Results
AQ
2018GREEN CROSS : GC Pharma Reports Q2 2018 Results
AQ
2018GREEN CROSS : GC Pharma to Establish Curevo - a Seattle-based New Company Dedica..
AQ
2018GREEN CROSS : GC Pharma to Establish Curevo - a Seattle-based New Company Dedica..
AQ
2018GREEN CROSS : GC Pharma Reports Q1 2018 Results
AQ
2018GREEN CROSS : GC Pharma Marks 'World Haemophilia Day'
AQ
2017GREEN CROSS CORP : Ex-dividend day for final dividend
FA
More news
Financials (KRW)
Sales 2019 1 377 B
EBIT 2019 70,5 B
Net income 2019 46,6 B
Debt 2019 170 B
Yield 2019 0,82%
P/E ratio 2019 36,51
P/E ratio 2020 30,76
EV / Sales 2019 1,40x
EV / Sales 2020 1,31x
Capitalization 1 759 B
Chart GREEN CROSS CORP
Duration : Period :
Green Cross Corp Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 177 091  KRW
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Eun-Cheol Huh President, Chief Executive Officer & Director
Byeong-Hwa Kim Director, Vice President & Head-Sales
In-Jae Lee Director & Head-Quality Management
Yoon-Jae Choi Outside Director
Il-Sup Huh Chairman-Executive Board